Multiple Myeloma

Updated phase 2 results of the MonumenTAL-1 study showed promising efficacy and a tolerable safety profile with talquetamab, a novel T-cell–redirecting bispecific antibody, in patients with RRMM.
Real-world analysis of patients with MM determines treatment patterns and survival outcomes in patients with t(11;14) compared to patients with high- and standard-risk cytogenetics.
REGN5458, a BCMAxCD38 bispecific antibody, demonstrated early durable responses with a tolerable safety profile and low rates of CRS in patients with relapsed/refractory multiple myeloma.
Phase 1 data of ALLO-715 followed by lymphodepletion showed durable responses in heavily pretreated RRMM patients.
Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients.
Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy.
Updated results from a phase 1 trial of subcutaneous isatuximab via OBDS continue to demonstrate an excellent local tolerability with comparable efficacy.
Implementation of a pharmacist on the healthcare team can have significant clinical and economic benefits.
In the first trial with this treatment regimen, quadruplet induction with Isa-KRd in patients with high-risk MM demonstrated promising activity and a tolerable safety profile.
Novel agent iberdomide demonstrated clinically meaningful activity and was generally well tolerated in a multicohort phase 1/2 trial.
Page 2 of 12
Results 11 - 20 of 114

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country